Q-omics provides the consensus-scored FGF21 profile across patient tissues and cancer cell-line models. FGF21 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FGF21 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FGF21 protein abundance shows 10,537 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where FGF21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGF21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGF21 survival associations across molecular data types. FGF21 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGF21 RNA expression–survival associations across cancer types. High FGF21 expression shows unfavorable associations in KIRC, ACC, KICH, UCEC, MESO and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FGF21 RNA expression.
This table summarizes FGF21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FGF21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGF21 shows lower tumor expression in CHOL and higher tumor expression in KIRC, UCEC, KIRP, KICH and LUSC. The KIRC box plot shows higher FGF21 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p = .034).
This table shows molecular features associated with FGF21 in patient tissues and cancer cell lines. In patient samples, FGF21 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FGF21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_SCLC.
